Yoshinari, Miku
Nishibata, Yuka
Masuda, Sakiko
Nakazawa, Daigo
Tomaru, Utano
Arimura, Yoshihiro
Amano, Koichi
Yuzawa, Yukio
Sada, Ken-Ei
Atsumi, Tatsuya
Dobashi, Hiroaki
Hasegawa, Hitoshi
Harigai, Masayoshi
Matsuo, Seiichi
Makino, Hirofumi
Ishizu, Akihiro
Article History
Received: 20 September 2022
Accepted: 10 December 2022
First Online: 16 December 2022
Declarations
:
: The use of human materials in this study was approved by the Ethical Committee of the Faculty of Health Sciences, Hokkaido University (permission nos. 18-34 and 18-68), and the experiments were performed in adherence with the Declaration of Helsinki.
: Not applicable.
: T.A. received research grants, speaking fees, and/or consultancy fees from AbbVie Inc., Alexion Inc., Asahi-Kasei Co., Astellas Pharma Inc., AstraZeneca plc., Bayer Yakuhin, Bristol-Myers Squibb Co., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Gilead Sciences K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Kyowa Kirin Co., Ltd., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd. Pfizer Inc., Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., and UCB Japan Co. Ltd. KE.S. received a speaker’s fee from Glaxo Smith Kline K.K. and a research grant from Pfizer Inc. H.M. served on steering committees for AbbVie Inc., and Teijin Pharma Ltd. and advisory boards for Nippon Boehringer Ingelheim Co., Ltd. and Travere Therapeutics.